An interventional study of Personalized 40 Hz Broadband Stimulation and 40 Hz Pure Tone Stimulation in Tinnitus, sponsored by Eye & ENT Hospital of Fudan University. Completed at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-10-27.
Sponsored by Eye & ENT Hospital of Fudan University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Tinnitus by Eye & ENT Hospital of Fudan University — 4 open to participants now, 4 under way, none of them phase 3. Tinnitus · Eye & ENT Hospital of Fudan University.
Among the 12 studies in Tinnitus by Eye & ENT Hospital of Fudan University, this one has the largest enrollment of the 11 interventional ones that give a count, is one of 2 that started in 2024, is one of 11 with no phase, and was the 7th registered.
446 studies on the registry are indexed under Tinnitus; 98 are open to participants now.
Browse Tinnitus studies →4 of the 12 studies in Tinnitus by Eye & ENT Hospital of Fudan University are open now, in 1 country. Recruiting first, the newest first:
Eye & ENT Hospital of Fudan University · Sites in China
Ages 18–80
Eye & ENT Hospital of Fudan University · Sites in China
Ages 18–65
Eye & ENT Hospital of Fudan University · Sites in China
Ages 18–70
Eye & ENT Hospital of Fudan University
Ages 18–60
By country, each count listing its studies:
Of the 49 Tinnitus studies recruiting now, 21 (43%) set no upper age limit and 18 (37%) stop at 75 or younger; 4 take children under 18; 10 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2015; this study’s year is marked. 2 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 363 is above the median of 60 across 370 interventional studies indexed under Tinnitus.
Median enrollment 162 across the 11 interventional studies, 225,792 across the 1 observational. Of the 5 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Eye & ENT Hospital of Fudan University is the lead sponsor of 127 studies on the registry; 71 are open to participants now.
1 of the studies in Tinnitus by Eye & ENT Hospital of Fudan University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07558837Eye & ENT Hospital of Fudan UniversityFudan Tinnitus Doctor for Tinnitus Management | 2027-05-30 |
Add it to your calendar (.ics) → With an account.
Among the 12 studies in Tinnitus by Eye & ENT Hospital of Fudan University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Tinnitus affects 10-15% of adults and is frequently associated with impaired quality of life, anxiety, and sleep disturbance. Conventional sound therapies based on continuous masking provide inconsistent and short-lived relief, and the neural mechanisms underlying residual inhibition (RI) remain unclear.
This study aims to determine whether 40 Hz burst stimulation with high-frequency carriers can achieve longer-lasting RI than continuous sound, and to explore its underlying neural mechanisms using EEG.
Residual inhibition (RI) refers to the temporary reduction or disappearance of tinnitus following sound stimulation and provides an important clue for identifying patients who may benefit from acoustic therapy. However, the effects of different sound stimulation strategies on RI remain poorly understood.
This study evaluates whether 40 Hz burst-modulated sound achieves stronger and longer RI compared with conventional continuous stimulation. The trial follows a four-phase design:
Phase 1: Exploratory testing of burst versus continuous tones at different frequencies.
Phase 2: Large-scale validation in 265 patients. Phase 3: Development of a personalized stimulation protocol using adaptive spectral optimization.
Phase 4: An independent EEG cohort undergoing a randomized crossover comparison of personalized burst and continuous broadband stimulation to investigate changes in gamma-band functional connectivity associated with residual inhibition.
The primary outcomes are the strength and duration of tinnitus suppression. Secondary outcomes include EEG-derived measures of source-space functional connectivity, quantified using phase-locking value (PLV) in the gamma band (38-42 Hz).
By combining behavioral and neurophysiological measures, this study aims to establish 40 Hz burst stimulation as a novel rhythm-based sound therapy and to provide mechanistic insights that may enable more effective, personalized tinnitus management.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive personalized broadband acoustic stimulation modulated at 40 Hz. An adaptive equalization algorithm, based on individual and population residual inhibition (RI) responses, is used to weight frequency components across 125 Hz-12 kHz.
Other: Personalized 40 Hz Broadband Stimulation
Participants receive pure tone stimulation at the individually optimized carrier frequency identified in earlier phases, amplitude-modulated at 40 Hz.
Other: 40 Hz Pure Tone Stimulation
Participants receive continuous broadband noise stimulation without 40 Hz modulation.
Other: Continuous Broadband Noise
Broadband acoustic stimulus (125 Hz-12 kHz) amplitude-modulated at 40 Hz with a 50% duty cycle. A polynomial regression and FFT-based algorithm applies individualized frequency weighting, combining population data (70%) and patient-specific responses (30%). Delivered for 60 seconds at 10 dB above the individual minimum masking level (MML).
Pure tone stimulus at the optimized frequency (matched to tinnitus characteristics or high-frequency carrier), amplitude-modulated at 40 Hz with a 50% duty cycle. Delivered for 60 seconds at 10 dB above MML.
Continuous broadband noise spanning 125 Hz-12 kHz without 40 Hz modulation. Delivered for 60 seconds at 10 dB above MML as an active control condition.
Tinnitus suppression strength
Residual inhibition depth, 0-100% reduction
Time frame: Immediately after the sound stimulation session.
Residual inhibition duration
Time in seconds until tinnitus returns to baseline after stimulation
Time frame: Immediately after the sound stimulation session.
EEG functional connectivity changes
Changes in source-space functional connectivity quantified using phase-locking value (PLV) in the gamma band (38-42 Hz), comparing stimulation and post-stimulation periods with baseline.
Time frame: measured across the entire 10-minute EEG recording session (baseline, during stimulation, and post-stimulation)
Plan to share: No
No publications or documents are linked to this record.
Ran from Oct 2024 to primary completion in Feb 2026, 15 months.
Of 134 non-industry interventional studies with no phase under Tinnitus, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 38. This study's 15 months is below that.
Counting every sponsor, half of 153 studies reached it within 17 months; a quarter within 10 and three quarters within 38.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 27, 2026: primary completion Jul 2025 → Feb 2026 and completion Jul 2025 → Feb 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Eye & ENT Hospital of Fudan University →